Juan Andrey Zarur - 02 Feb 2022 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC

Role: President & CEO, Director
Signature: /s/ David Kennedy, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 02 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 04 Feb 2022, 18:26:38 UTC
Next filing: 26 Jul 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GRNA	Common Stock	Award		+896,058			896,058	02 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GRNA	Stock Option (Right to Buy)	Award		+70,319			70,319	02 Feb 2022	Common Stock	70,319	$0.3500	Direct	F2, F3
transaction	GRNA	Stock Option (Right to Buy)	Award		+926,330			926,330	02 Feb 2022	Common Stock	926,330	$0.3300	Direct	F3, F4
transaction	GRNA	Stock Option (Right to Buy)	Award		+1,982,609			1,982,609	02 Feb 2022	Common Stock	1,982,609	$0.5000	Direct	F3, F5
transaction	GRNA	Stock Option (Right to Buy)	Award		+668,830			668,830	02 Feb 2022	Common Stock	668,830	$0.5000	Direct	F3, F6
transaction	GRNA	Stock Option (Right to Buy)	Award		+1,906,944			1,906,944	02 Feb 2022	Common Stock	1,906,944	$0.9800	Direct	F3, F7
transaction	GRNA	Stock Option (Right to Buy)	Award		+292,649			292,649	02 Feb 2022	Common Stock	292,649	$0.9800	Direct	F3, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Issued pursuant to the terms of a business combination agreement involving the issuer and GreenLight Biosciences, Inc. in exchange for capital stock previously issued by such company.
F2	100% of the shares subject to this option are fully vested and exercisable.
F3	This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company.
F4	20% of the shares underlying the option vested or shall vest on September 12, 2018 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting October 12, 2018.
F5	20% of the shares underlying the option vested or shall vest on December 5, 2020 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting December 5, 2021.
F6	20% of the shares underlying the option vested or shall vest on December 5, 2020 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting December 5, 2021.
F7	25% of the shares underlying the option vested or shall vest on December 1, 2021 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting January 1, 2022.
F8	25% of the shares underlying the option vested or shall vest after one year of service and the remainder of the shares vested or shall vest in 36 equal monthly installments.